Skip to content

Tranexamic acid for Hematoma Expansion and Peri-Hematomal Edema in Patients with Acute Intracerebral Hemorrhage: a randomized, placebo-controlled trial

Tranexamic acid for Hematoma Expansion and Peri-Hematomal Edema in Patients with Acute Intracerebral Hemorrhage: a randomized, placebo-controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027065
Enrollment
Unknown
Registered
2019-10-30
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracerebral hemorrhage

Interventions

control group:sodium chloride 0.9%

Sponsors

The Fifth Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients were more than 18 years old; 2. Spontaneous intracerebral hemorrhage was documented by CT scanning within 4.5 hours of the onset of symptoms; 3. No planned surgery.

Exclusion criteria

Exclusion criteria: 1. No identified secondary cause of ICH, including anticoagulation, thrombolysis or known underlying structural abnormality such as arteriovenous malformation, aneurysm, tumor, or venous thrombosis. An underlying structural abnormality does not need to be excluded before enrolment, but where known, patients should not be recruited; 2. Contraindication to tranexamic acid; 3. Life expectancy is less than 3 months; 4. Malignant tumor, participation in another interventional trial; 5. Premorbid dependency (mRS > 4).

Design outcomes

Primary

MeasureTime frame
hematoma volume;Peri-Hematomal Edema;

Countries

China

Contacts

Public ContactJiang Chao

Department of Neurology, the Fifth Affiliated Hospital of Zhengzhou University

chaojzzu@126.com+86 0371-66916128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026